Zevra Therapeutics (ZVRA) News Today $7.68 -0.15 (-1.92%) Closing price 04:00 PM EasternExtended Trading$7.66 -0.01 (-0.20%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni Sells 3,000 SharesZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy J. Sangiovanni sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $23,580.00. Following the completion of the transaction, the senior vice president now owns 16,341 shares of the company's stock, valued at approximately $128,440.26. This trade represents a 15.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.February 15, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) EVP Sells $82,530.00 in StockZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares of the company's stock, valued at approximately $231,759.96. This trade represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.February 15, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO Sells $86,460.00 in StockZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 15, 2025 | marketbeat.comNeil F. Mcfarlane Sells 61,273 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) StockZevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares of the company's stock, valued at $1,745,391.60. The trade was a 21.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.February 15, 2025 | marketbeat.comInsider Selling: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Sells 3,000 Shares of StockFebruary 15, 2025 | insidertrades.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by BrokeragesFebruary 15, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by AnalystsShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received an average recommendation of "Buy" from the eight brokerages that are covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buFebruary 15, 2025 | marketbeat.comZevra Therapeutics exec sells $23,587 in stockFebruary 14, 2025 | msn.comWhat is Roth Capital's Estimate for ZVRA FY2029 Earnings?February 13, 2025 | americanbankingnews.comQ1 EPS Forecast for Zevra Therapeutics Lifted by AnalystFebruary 13, 2025 | americanbankingnews.comRoth Capital Predicts Higher Earnings for Zevra TherapeuticsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Roth Capital lifted their Q1 2025 EPS estimates for Zevra Therapeutics in a research report issued on Sunday, February 9th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.27) per share for the quarter, up fromFebruary 12, 2025 | marketbeat.comFY2029 Earnings Estimate for ZVRA Issued By Roth CapitalZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for shares of Zevra Therapeutics in a note issued to investors on Sunday, February 9th. Roth Capital analyst J. Aschoff expects that the company willFebruary 11, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Stratos Wealth Partners LTD.Stratos Wealth Partners LTD. trimmed its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 335,840 shares of the company's stock aFebruary 8, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to Strong-Buy RatingCantor Fitzgerald upgraded shares of Zevra Therapeutics to a "strong-buy" rating in a research note on Wednesday.January 30, 2025 | marketbeat.comZevra Therapeutics to Present at the 21st Annual WORLDSymposium™January 30, 2025 | globenewswire.comZevra Therapeutics to Participate at Upcoming Investor ConferencesJanuary 29, 2025 | globenewswire.comCantor Fitzgerald Predicts ZVRA FY2025 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Comments on ZVRA FY2025 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the companJanuary 23, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by AnalystsShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus rating of "Buy" by the eight research firms that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating toJanuary 21, 2025 | marketbeat.comBarclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Barclays PLC raised its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 292.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 57,599 shares of the company's stock after purchasing an additional 42,926 shares during the quaJanuary 19, 2025 | marketbeat.comPositive Signs As Multiple Insiders Buy Zevra Therapeutics StockJanuary 16, 2025 | finance.yahoo.comFY2024 EPS Estimates for ZVRA Increased by Cantor FitzgeraldZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Cantor Fitzgerald raised their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn ($1.93) peJanuary 10, 2025 | marketbeat.comZevra Therapeutics assumed with an Overweight at Cantor FitzgeraldJanuary 8, 2025 | markets.businessinsider.comZevra Therapeutics (ZVRA) Receives a Buy from Cantor FitzgeraldJanuary 8, 2025 | markets.businessinsider.comZevra Therapeutics (NASDAQ:ZVRA) Now Covered by Cantor FitzgeraldCantor Fitzgerald initiated coverage on shares of Zevra Therapeutics in a report on Wednesday. They set an "overweight" rating and a $25.00 price objective on the stock.January 8, 2025 | marketbeat.comGeode Capital Management LLC Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Geode Capital Management LLC increased its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 14.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,043,864 shares of the company's stock after purchasing an additional 129,600 shareJanuary 3, 2025 | marketbeat.comSanctuary Advisors LLC Has $194,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Sanctuary Advisors LLC reduced its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 73.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,924 shares of the company's stock after selling 77,000 shares during the period. SanctuDecember 30, 2024 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given an average rating of "Buy" by the eight analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong bDecember 27, 2024 | marketbeat.comZevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024December 17, 2024 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Lifted by Fmr LLCFmr LLC lifted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 282,687.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,313,202 shares of the company's stock after purchasing an additional 2December 11, 2024 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stakeDecember 6, 2024 | uk.finance.yahoo.comZevra Therapeutics Announces Organizational ChangesDecember 6, 2024 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Buy" by BrokeragesShares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned an average recommendation of "Buy" from the eight analysts that are covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a stronDecember 2, 2024 | marketbeat.comVestal Point Capital LP Purchases New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 525,000 shares of the company's stock, valued at approximately $November 29, 2024 | marketbeat.comPropel Bio Management LLC Invests $1.25 Million in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Propel Bio Management LLC bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 179,874 shares of the company's stock, valuNovember 26, 2024 | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comZevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA(TM) (arimoclomol) for Treatment of Niemann-Pick Disease Type CNovember 24, 2024 | stockhouse.comZevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week High - Should You Buy?Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week High - Still a Buy?November 22, 2024 | marketbeat.comZevra Therapeutics Launches MIPLYFFA for Niemann-Pick DiseaseNovember 22, 2024 | msn.comResearch Analysts Offer Predictions for ZVRA FY2024 EarningsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Zevra Therapeutics in a report released on Wednesday, November 20th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($1.92)November 22, 2024 | marketbeat.comZevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CNovember 21, 2024 | globenewswire.comHC Wainwright Expects Lower Earnings for Zevra TherapeuticsZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Zevra Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst O. Livnat now expects that the company will earn $2.51 per shaNovember 21, 2024 | marketbeat.comZevra Therapeutics’ MIPLYFFA Launch Drives Strong Buy Rating Amidst Growth ProspectsNovember 20, 2024 | markets.businessinsider.comZevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday.November 20, 2024 | marketbeat.comZVRA FY2024 EPS Forecast Decreased by Cantor FitzgeraldZevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company willNovember 18, 2024 | marketbeat.comWhat is William Blair's Forecast for ZVRA FY2024 Earnings?Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair dropped their FY2024 earnings per share estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, November 13th. William Blair analyst S. Corwin now anticipates that the company will postNovember 18, 2024 | marketbeat.comAnalysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter ReportNovember 16, 2024 | uk.finance.yahoo.comZevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comZevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Makes New $833,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,000 shares of theNovember 15, 2024 | marketbeat.com Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVRA Media Mentions By Week ZVRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVRA News Sentiment▼0.370.60▲Average Medical News Sentiment ZVRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVRA Articles This Week▼73▲ZVRA Articles Average Week Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Iovance Biotherapeutics News Praxis Precision Medicines News Galapagos News Wave Life Sciences News Apogee Therapeutics News Evotec News Disc Medicine News Arcutis Biotherapeutics News Amphastar Pharmaceuticals News Immunocore News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVRA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZVRA Stock Alerts